Opdivo® (nivolumab) in Combination with CABOMETYX®

Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to sunitinib, regardless of IMDC risk scoreThese three-year data – with a median follow-up of 44 months – from CheckMate -9ER r...

Related Keywords

China , Japan , Chile , Santiago , Regióetropolitana , United States , America , American , Dana Walker , Claire Mcconnaughey , Mauricio Burotto , Susan Hubbard , Vickil Goodman , Company Opdivo , American Society Of Clinical Oncology , Bradford Hill Clinical Research Center , Nasdaq , Takeda Pharmaceutical Company , International Metastatic Renal Cell Carcinoma Database Consortium , Exelixis Inc , Public Affairs , Ono Pharmaceutical Co , European Union , Product Development Medical Affairs , Bristol Myers Squibb , American Society , Clinical Oncology , Cancers Symposium , Hazard Ratio , Confidence Interval , Bristol Myers , Executive Vice President , Product Development , Medical Affairs , Chief Medical Officer , Myers Squibb , Ono Pharmaceutical , Ipsen Pharma , North America , Better Future , Fatal Immune Mediated Adverse , Full Prescribing Information , Investor Relations ,